SCI Abstract

search
+
Cadonilimab is effective and safe in recurrent cervical cancer
The standard-of-care (SOC) first-line treatment for patients with recurrent or metastatic cervical cancer is chemotherapy ...
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress
Author notesThese authors contributed equally: Shelley A. Jazowski, Rahul K. Nayak.Authors and AffiliationsDepartment of H...
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
The B cell receptor (BCR) signalling pathway has an integral role in the pathogenesis of many B cell malignancies, includi...
On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients?
A number of therapeutics that target mediators of signalling in the hypothalamic and brainstem regions that control appeti...
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?
The DESTINY-Breast06 trial investigated earlier and broader use of trastuzumab deruxtecan in patients with metastatic horm...
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes
Approximately 40% of hormone receptor-positive (HR+), HER2-negative (HER2–) breast cancers harbour activating mutations in...
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Chimeric antigen receptor (CAR) T cells are revolutionizing cancer therapy, particularly for haematological malignancies, ...
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
Over the past few years, several novel systemic treatments have emerged for patients with treatment-refractory metastatic ...
Targeting cuproplasia and cuproptosis in cancer
Targeting cuproplasia and cuproptosis in cancer
Copper, an essential trace element that exists in oxidized and reduced forms, has pivotal roles in a variety of biological...
Claudin 18.2 as a novel therapeutic target
Claudin 18.2 as a novel therapeutic target
Claudin 18.2, a tight-junction molecule predominantly found in the nonmalignant gastric epithelium, becomes accessible on ...
A new standard of care for advanced-stage urothelial carcinoma
Eligible patients with advanced-stage urothelial carcinoma (UC) typically receive platinum-based chemotherapy as first-lin...
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges
The composition of the gut microbiota has emerged as a tumour-extrinsic factor that modulates response to immune-checkpoin...
IL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas
The efficacy of chimeric antigen receptor (CAR) T cell therapy for solid tumours has been disappointing to date. However, ...
Enhancing diagnostic precision in liver lesion analysis using a deep learning-based system: opportunities and challenges
A recent study reported the development and validation of the Liver Artificial Intelligence Diagnosis System (LiAIDS), a f...
Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer
Patients with recurrent, platinum-sensitive epithelial ovarian cancer (defined as disease relapse ≥6 months after first-li...
Global epidemiology of epithelial ovarian cancer
Global epidemiology of epithelial ovarian cancer
Globally, ovarian cancer is the eighth most common cancer in women, accounting for an estimated 3.7% of cases and 4.7% of ...
Patients with uncommon EGFR mutations also benefit from first-line osimertinib
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab
Recent results from the FLAURA2 and MARIPOSA-2 trials underline the continued role of chemotherapy in the treatment of pat...
Personalizing adjuvant therapy for patients with colorectal cancer
Personalizing adjuvant therapy for patients with colorectal cancer
The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC) comprises a fluoropyrim...
Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients
Neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy with pelvic lymphadenectomy is the cur...
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell malignancies or relapsed and/or...
From the ESMO Congress 2023
As in 2017, this year’s ESMO Congress brought many members of the oncology community together in Madrid, this time with &g...
Computational immunogenomic approaches to predict response to cancer immunotherapies
Computational immunogenomic approaches to predict response to cancer immunotherapies
Cancer immunogenomics is an emerging field that bridges genomics and immunology. The establishment of large-scale genomic ...
THOR provides new data on the efficacy of erdafitinib
The outcomes of patients with metastatic urothelial carcinoma (mUC) and non-muscle invasive urothelial carcinoma (NMIBC) f...
Activity of selpercatinib confirmed in phase III trials
In May 2020, the FDA granted Accelerated Approval to the RET kinase inhibitor selpercatinib for patients with metastatic n...
From ESMO 2023: advances in lung cancer
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
From CHRYSALIS to PAPILLON: the metamorphosis of amivantamab into frontline therapy for NSCLC
In 2021, data from the phase I CHRYSALIS trial supported the FDA Accelerated Approval of amivantamab, an EGFR–MET bispecif...
Progress in systemic therapy for advanced-stage urothelial carcinoma
Progress in systemic therapy for advanced-stage urothelial carcinoma
Despite recent advances, advanced-stage urothelial carcinoma (aUC) remains incurable, with 5-year survival rates of approx...
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs
Projected increases of cancer-attributable health-care costs, accompanied by staff shortages, will impose future economic ...
Molecular tumour boards — current and future considerations for precision oncology
Molecular tumour boards — current and future considerations for precision oncology
Over the past 15 years, rapid progress has been made in developmental therapeutics, especially regarding the use of matche...
Load More
format_indent_increase